Kimberly-Clark eyes five-part bond sale for $36B Kenvue deal
Alpha Vantage · Quartz · · AI-summarised by FinFlash
Kimberly-Clark is considering a five-part bond sale to help finance its acquisition of Kenvue, the maker of Tylenol. JPMorgan Chase is coordinating investor calls for the potential offering, which could mature in two to ten years. The bond sale aims to replace bridge financing for the $36 billion deal, of which $6.7 billion is cash.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.